Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Cirrhosis

Last updated: May 5, 2021

Summarytoggle arrow icon

Cirrhosis is a condition caused by chronic damage to the liver, most commonly due to excessive alcohol consumption, nonalcoholic fatty liver disease, or hepatitis C infection. Other causes may include inflammatory or metabolic diseases, such as primary biliary cirrhosis or hemochromatosis. Cirrhosis is characterized by hepatic parenchymal necrosis and an inflammatory response to the underlying cause. Subsequent hepatic repair mechanisms lead to fibrosis and abnormal tissue architecture, which impair liver function. Patients can present with a range of symptoms, including ascites, hepatosplenomegaly; and skin manifestations of cirrhosis, such as jaundice, spider angioma, and/or palmar erythema. Men may further display signs of feminization (e.g., gynecomastia, hypogonadism). In severe cases, accumulation of toxic metabolites or involvement of further organs can lead to complications such as hepatic encephalopathy or hepatorenal syndrome. Laboratory tests show signs of hepatocyte damage (e.g., elevated liver enzymes, hyperbilirubinemia) or impaired hepatic synthetic function (e.g., prolonged prothrombin time, low albumin). Abdominal ultrasonography typically shows shrunken, heterogeneous liver parenchyma with a nodular surface. A biopsy is the method of choice for confirming the diagnosis. However, it is usually only performed if previous diagnostic modalities were inconclusive. Management consists of treatment of the underlying disease (e.g., avoiding toxic substances, antiviral drugs), adequate caloric intake, and medication for treating complications (e.g., spironolactone for ascites). In cases of decompensated cirrhosis, interventional procedures (e.g., paracentesis to drain ascites) may be used to alleviate symptoms or bridge the time until liver transplantation is possible.

  • Prevalence: approx. 0.27% in US adults [1]
  • Sex: > (2:1) [2]
  • Mortality [2]
    • Responsible for approx. 1–2% of all deaths in the US (12th leading cause of death)
    • Most deaths occur in the fifth to sixth decade of life.

Epidemiological data refers to the US, unless otherwise specified.

Cryptogenic cirrhosis is a diagnosis of exclusion and should only be considered after a complete patient evaluation has ruled out all other possible causes of cirrhosis.

Hepatitis C, alcoholic liver disease, and NASH are the most common causes of cirrhosis in the US.

Clinical manifestations of liver cirrhosis generally represent the severity of liver disease. [6]

Laboratory tests [6]

Complete blood count (CBC)

Liver function tests

Other laboratory tests

Additional laboratory studies can be performed to determine the etiology of chronic liver disease.

Imaging studies

  • Abdominal ultrasound
    • Best initial imaging study
    • Liver form and structure findings
      • Nodular liver surface
      • Atrophy of the right lobe
      • Loss of structural homogeneity (hyperechoic or variable increase in echogenicity) with fibrous septa
    • Liver size findings
      • Initially enlarged
      • Atrophies and shrinks with disease progression
    • Other possible findings
  • CT scan
  • Transient elastography
    • Ultrasound technique used to measure liver elasticity
    • Allows for monitoring of patients with chronic liver disease and helps with early diagnosis of increased fibrosis and progression to cirrhosis

Biopsy

  • Execution: usually ultrasound‑guided transcutaneous approach (easily performed, but may have limited diagnostic value if only a small tissue sample can be taken)
  • Indications: Biopsy is the gold standard for diagnosis of cirrhosis. However, it should only be considered if clinical, laboratory, and ultrasound evidence is unclear.
  • Alternative methods
    • Laparoscopic biopsy Large biopsies can be obtained.
    • Transjugular biopsy (transvenous biopsy)
      • For severely obese patients or patients with ascites.
      • There is a lower risk of bleeding in comparison to a standard biopsy.
      • A transjugular biopsy is especially useful if TIPS is planned.

Before taking a biopsy, check the patient's coagulation status as the risk of bleeding may be increased.

Monitoring the disease course

Patients diagnosed with cirrhosis should repeat laboratory tests every 6 months to recalculate the Child-Pugh score and Model for End-Stage Liver Disease (MELD) scores (see “Prognosis” below).

  • Fibrosis (fibrous septa)
  • Replacement of normal liver tissue with collagenous regenerative nodules (histological staging is based on the size of the regenerative nodules) [6]
  • Abnormal cell activation with infiltration of inflammatory cells
  • Loss of physiological vessel architecture (central vein disappearance)
Size of the regenerative nodules Occurrence
Micronodular
  • 1–3 mm
Macronodular
  • > 3 mm
Both
  • 1–3 mm and > 3 mm
  • Possible in every type of liver‑damaging disease

General approach [11][12]

Pharmacotherapy

Surgical/Interventional procedures [13]

Cirrhosis associated ascites and edema, as well as the high risk of bleeding, increase the risk for hypovolemic shock.

We list the most important complications. The selection is not exhaustive.

Definition [12][14]

  • Fluctuations in mental status and cognitive function in the presence of severe liver disease (e.g., cirrhosis)

Pathophysiology [15][16]

Precipitant factors [16]

Clinical features

Symptoms are usually reversible.

Diagnostics

  • Based on the patient's medical history and clinical presentation
  • Assessment of mental status
    • Number connection test: test in which patients are timed while connecting numbers in order that are randomly distributed over a piece of paper (in hepatic encephalopathy it is completed slower than the age-normalized standard or not completed)
    • Psychometry‑based diagnostic method (e.g., Mini-Mental State Examination) [17][18]
  • Laboratory studies: elevated serum ammonia levels

Treatment

Definition

  • Deterioration of kidney function in patients with advanced liver disease

Pathophysiology [19][20]

Risk factors

Generally attributed to the loss of volume

Clinical features [19]

Diagnosis

Hepatorenal syndrome is a clinical diagnosis based on reduced glomerular filtration rate in patients with cirrhosis and no other causes for renal failure (e.g., shock) or no detection of renal pathologies on ultrasound.

Treatment

Definition [22]

Pathophysiology

Etiology

Clinical features

Depend on the extent of thrombosis and the speed of manifestation

Diagnostics

When PVT is detected in patients with cirrhosis, HCC must be ruled out as the cause.

Treatment [23]

The goal is to prevent precipitant factors, thrombosis extension, and achieve portal vein recanalization. There are no generalized management recommendations for cirrhotic patients with portal vein thrombosis.

Hepatopulmonary syndrome [25][26]

Definition

Pathophysiology

Clinical features

Diagnostics [27]

Treatment [26]

  • Supportive measures: Long‑term treatment with oxygen is recommended.
  • Surgical procedure: liver transplant

Portopulmonary hypertension [28][29]

Definition

Pathophysiology

Clinical features

Diagnostics

Treatment

Other pulmonary complications in cirrhosis

Liver transplantation should be considered when medical treatment of cirrhosis has failed. Risk stratification for liver transplant is done by using the Model for End-Stage Liver Disease (MELD score) and Child-Pugh score systems. [11]

Child-Pugh score

  • A prognostic grading scale to assess the severity of cirrhosis, on the basis of specific laboratory markers (e.g., bilirubin, albumin, prothrombin time), as well as ascites and encephalopathy
    • Can be used as a prognostic scoring system [31]
      • Child‑Pugh class A: almost normal
      • Child‑Pugh class B: one-year survival rate of approx. 80%
      • Child‑Pugh class C: one-year survival rate of approx. 45%
    • In patients with decompensated cirrhosis survival is poor, unless they receive liver transplantation.
Child-Pugh score
Points 1 2 3
Serum albumin g/dL > 3.5 2.8–3.5 < 2.8
Serum bilirubin mg/dL < 2.0 2.0–3.0 > 3.0
INR < 1.7 1.7–2.3 > 2.3
Ascites None Mild Moderate
Hepatic encephalopathy None Minimal Advanced
Child-Pugh class A: 5–6 points; Child-Pugh class B: 7–9 points; Child-Pugh class C: 10–15 points

CHILD's ABCDEs: Albumin, Bilirubin, Coagulation (e.g., INR), Distended abdomen (ascites), and Encephalopathy.

MELD score

  • An additional model used to predict prognosis in patients with cirrhosis, in terms of three-month mortality
  • Primarily used to prioritize patients needing liver transplantation
  • Patients are given a score from 1–40 based on serum bilirubin, INR, and creatinine levels.
  • The higher the score, the worse the prognosis.
  1. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  2. Meng F, Yin X, Ma X, Guo XD, Jin B, Li H. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients. Biomed Rep. 2013; 1 (2): p.265-268. doi: 10.3892/br.2013.60 . | Open in Read by QxMD
  3. Nusrat S. Cirrhosis and its complications: Evidence based treatment. World Journal of Gastroenterology. 2014; 20 (18): p.5442. doi: 10.3748/wjg.v20.i18.5442 . | Open in Read by QxMD
  4. Mansour D, McPherson S. Management of decompensated cirrhosis.. Clin Med. 2018; 18 (Suppl 2): p.s60-s65. doi: 10.7861/clinmedicine.18-2-s60 . | Open in Read by QxMD
  5. Kapoor B, Sands M, Copelan A. Transjugular Intrahepatic Portosystemic Shunt: Indications, Contraindications, and Patient Work-Up. Seminars in Interventional Radiology. 2014; 31 (03): p.235-242. doi: 10.1055/s-0034-1382790 . | Open in Read by QxMD
  6. Tsoris A, Marlar CA. Use Of The Child Pugh Score In Liver Disease. StatPearls. 2020 .
  7. Vilstrup H. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014; 61 (3): p.642-659. doi: 10.1016/j.jhep.2014.05.042 . | Open in Read by QxMD
  8. Cudalbu C, Taylor-Robinson SD. Brain Edema in Chronic Hepatic Encephalopathy. Journal of Clinical and Experimental Hepatology. 2019; 9 (3): p.362-382. doi: 10.1016/j.jceh.2019.02.003 . | Open in Read by QxMD
  9. Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy.. Gastroenterology & hepatology. 2011; 7 (4): p.222-33.
  10. Torres DS, Abrantes J, Brandão-mello CE. Cognitive assessment of patients with minimal hepatic encephalopathy in Brazil. Metab Brain Dis. 2013; 28 (3): p.473-483. doi: 10.1007/s11011-013-9405-3 . | Open in Read by QxMD
  11. Li SW, Wang K, Yu YQ, Wang HB, Li YH, Xu JM. Psychometric hepatic encephalopathy score for diagnosis of minimal hepatic encephalopathy in China. World J Gastroenterol. 2013; 19 (46): p.8745-8751. doi: 10.3748/wjg.v19.i46.8745 . | Open in Read by QxMD
  12. Ng CK, Chan MH, Tai MH, Lam CW. Hepatorenal syndrome.. The Clinical biochemist. Reviews. 2007; 28 (1): p.11-7.
  13. Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK. Hepatorenal Syndrome. Clinical Journal of the American Society of Nephrology. 2019; 14 (5): p.774-781. doi: 10.2215/cjn.12451018 . | Open in Read by QxMD
  14. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019; 71 (4): p.811-822. doi: 10.1016/j.jhep.2019.07.002 . | Open in Read by QxMD
  15. Ponziani FR. Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. World Journal of Gastroenterology. 2010; 16 (2): p.143. doi: 10.3748/wjg.v16.i2.143 . | Open in Read by QxMD
  16. Wu M, Schuster M, Tadros M. Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. Journal of Clinical and Translational Hepatology. 2019; 7 (X): p.1-11. doi: 10.14218/jcth.2018.00057 . | Open in Read by QxMD
  17. Primignani M. Portal vein thrombosis, revisited. Digestive and Liver Disease. 2010; 42 (3): p.163-170. doi: 10.1016/j.dld.2009.08.003 . | Open in Read by QxMD
  18. Lv Y, Fan D. Hepatopulmonary Syndrome. Dig Dis Sci. 2015; 60 (7): p.1914-1923. doi: 10.1007/s10620-015-3593-0 . | Open in Read by QxMD
  19. Grilo-Bensusan I, Pascasio-Acevedo JM. Hepatopulmonary syndrome: What we know and what we would like to know. World Journal of Gastroenterology. 2016; 22 (25): p.5728. doi: 10.3748/wjg.v22.i25.5728 . | Open in Read by QxMD
  20. Grilo Bensusan I, Pascasio JM, Tirado JL, et al. The utility of the macro-aggregated albumin lung perfusion scan in the diagnosis and prognosis of hepatopulmonary syndrome in cirrhotic patients candidates for liver transplantation. Revista Española de Enfermedades Digestivas. 2017 . doi: 10.17235/reed.2017.4219/2016 . | Open in Read by QxMD
  21. Saleemi S. Portopulmonary hypertension. Ann Thorac Med. 2010; 5 (1): p.5. doi: 10.4103/1817-1737.58953 . | Open in Read by QxMD
  22. Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, Charlton MR, Duarte-Rojo A. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. European Respiratory Review. 2012; 21 (125): p.223-233. doi: 10.1183/09059180.00007211 . | Open in Read by QxMD
  23. Krok KL. Hepatic hydrothorax: Current concepts. Clinical Liver Disease. 2014; 4 (2): p.35-37. doi: 10.1002/cld.375 . | Open in Read by QxMD
  24. Scaglione S, Kliethermes S, Cao G, et al. The Epidemiology of Cirrhosis in the United States: A Population-based Study.. Journal of Clinical Gastroenterology. 2015; 49 (8): p.690-696. doi: 10.1097/mcg.0000000000000208 . | Open in Read by QxMD
  25. Yoon, Chen. LIVER CIRRHOSIS MORTALITY IN THE UNITED STATES:NATIONAL, STATE, AND REGIONAL TRENDS, 2000–2015. U.S. Department of Health and Human Services Public Health Service National Institutes of Health. 2018 .
  26. Kuniholm MH, Lesi OA, Mendy M, et al. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa.. Environ Health Perspect. 2008; 116 (11): p.1553-7. doi: 10.1289/ehp.11661 . | Open in Read by QxMD
  27. Garcia-Tsao G, Korzenik JR, Young L, et al. Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia. N Engl J Med. 2000; 343 (13): p.931-936. doi: 10.1056/nejm200009283431305 . | Open in Read by QxMD
  28. Goljan EF. Rapid Review Pathology. Elsevier Saunders ; 2018
  29. Nevzati E, Shafighi M, Bakhtian KD, Treiber H, Fandino J, Fathi AR. Estrogen Induces Nitric Oxide Production Via Nitric Oxide Synthase Activation in Endothelial Cells. Springer International Publishing ; 2014 : p. 141-145
  30. Cavanaugh J, Niewoehner CB, Nuttall FQ. Gynecomastia and cirrhosis of the liver. Arch Intern Med. 1990; 150 (3): p.563-565.
  31. Meseeha M, Attia M. Alpha 1 Antitrypsin Deficiency. StatPearls. 2020 .
  32. Herold G. Internal Medicine. Herold G ; 2014
  33. Underlying cause of death 1999-2018 on CDC WONDER online database..